Valued at USD 4.42 billion in 2024, the base year, the single-use bioreactors market is projected to reach USD 4.81 billion in 2025 and USD 10.42 billion by 2034, growing at a CAGR of 9.0% during the forecast period 2025–2034, per Polaris Market Research. Rising demand for biologics and biosimilars, which requires efficient and cost-effective production methods, together with wider adoption of bioprocessing technologies, is driving expansion. Key players shaping supply include Thermo Fisher Scientific, Sartorius AG, Merck KGaA, Danaher Corporation, Pall Corporation, Repligen Corporation, Lonza Group, and Saint-Gobain.

Cell Type and End-Use Segmentation

By cell type, the market spans mammalian, bacterial, and yeast cells. The mammalian cell segment holds the largest share and is registering the highest growth, reflecting the role of mammalian cell culture in producing complex biologics, including monoclonal antibodies and therapeutic proteins. Bacterial cells are commonly used for simpler proteins and enzymes, while yeast cells are used for their ability to perform post-translational modifications; both segments grow more slowly. The complexity of mammalian cell culture, coupled with the high-value products it generates, underscores its importance in the biopharmaceutical industry.

By end use, pharmaceutical and biopharmaceutical companies hold the largest share and the highest growth, driven by demand for biologics, the need for cost-effective production, and the development of new therapeutic products. The CROs & CMOs segment is supported by the trend of outsourcing biomanufacturing, as contract research and contract manufacturing organizations use single-use bioreactors to provide flexible, scalable solutions to clients. Academic and research institutes use them for experimental and developmental purposes, with relatively lower demand.

Browse Insights:

https://www.polarismarketresearch.com/industry-analysis/single-use-bioreactors-market

Consumables in the Single-Use Bioreactors Market

Beyond core systems, single-use media bags and single-use filtration assemblies are experiencing steady demand. Media bags are essential for storing and transporting culture media, while filtration assemblies are crucial for separating and purifying biological products. Their growth is described as more incremental than that of bioreactor systems, though both contribute significantly to the overall market, and emphasis on improving bioreactor system performance continues to drive the majority of advancements and investments.

Regional Insights

North America holds the largest share, owing to its biopharmaceutical industry, research infrastructure, and a network of pharmaceutical companies, contract manufacturers, and research institutions, while leadership in technological innovation and regulatory advancements bolsters its position. Europe, where Germany, Switzerland, and the UK contribute significantly, benefits from a strong presence of pharmaceutical and biotech firms, stringent regulatory frameworks that support single-use adoption, and increased government funding for biotech research and development. Asia Pacific is witnessing rapid expansion, with China and India at the forefront of investment in biopharmaceutical manufacturing.

Recent Capacity Developments

• May 2025: eureKING acquired Skyepharma to boost its biomanufacturing capabilities, strengthen its presence in European biologics production, and support demand for single-use bioreactor technologies.
• April 2025: AGC Biologics announced investment in large-scale single-use technology at its new Yokohama facility, including two 5,000 L Thermo Scientific DynaDrive single-use bioreactors.
• April 2025: WuXi Biologics completed its first commercial Process Performance Qualification (PPQ) campaign at its MFG20 facility in Hangzhou, China, using three 5,000 L single-use bioreactors.

Competitive Landscape

Players are investing in research and development to advance single-use bioreactor technology, with a focus on improving efficiency, reducing costs, and integrating automation and digital monitoring. Merck KGaA and GE Healthcare offer integrated solutions combining bioreactor systems with advanced analytics, while Repligen and Pall Corporation are noted for specialized solutions and continuous product development. The report's Porter's Five Forces analysis rates rivalry among existing firms as high and the threat of new entrants as low. Key players include Thermo Fisher Scientific, Sartorius AG, Eppendorf AG, Merck KGaA, GE Healthcare, Danaher Corporation, Pall Corporation, Repligen Corporation, Lonza Group, ABEC, Applikon Biotechnology, Celltech Pharma, Fujifilm Irvine Scientific, Hamilton Company, and Saint-Gobain.

More Trending Latest Reports By Polaris Market Research:

bioregenerative-aesthetic-injectables-market

industrial-dryer-market

customer-success-management-market

aquaculture-market

feed-mycotoxin-detoxifiers-market

us-integrated-delivery-network-market

data-center-logistics-market

integrated-delivery-network-market

value-based-healthcare-services-market

computational-photography-market